GVP Module VII: PSUR Scope, Objectives and Regulatory Purpose

Introduction

The Periodic Safety Update Report (PSUR) is one of the principal mechanisms through which the European Union periodically evaluates whether new information has changed the known safety profile or benefit-risk balance of a medicinal product or active substance.

The PSUR should therefore be understood as a regulatory safety-evaluation process, not merely as a recurring report that collects adverse-event data.

Its purpose is to bring relevant evidence together at defined intervals, evaluate that evidence scientifically, identify changes in the safety profile and determine whether further pharmacovigilance or regulatory action may be required.

This distinction is fundamental to understanding GVP Module VII.

1. What Is the Regulatory Purpose of a PSUR?

The central purpose of the PSUR is periodic evaluation of the safety profile and benefit-risk balance using the information that has become available during the reporting interval together with relevant cumulative knowledge.

The report therefore provides a structured opportunity to ask:

• What new safety information has emerged?
• What does that information mean clinically?
• Does it change the understanding of an existing risk?
• Does it identify a new or changing safety concern?
• Does it alter the overall benefit-risk assessment?
• Is additional action required?

The PSUR is consequently an assessment document. The underlying data are important, but their regulatory value depends on the quality of the analysis and conclusions drawn from them.

2. The PSUR in the Pharmacovigilance Lifecycle

The PSUR operates within a wider system rather than as an isolated activity.

A simplified relationship is:

Safety information from multiple sources
                    ↓
          Continuous PV activities
                    ↓
        Periodic safety evaluation
                    ↓
                  PSUR
                    ↓
          Benefit-risk conclusion
                    ↓
       PV / risk-management action
                    ↓
        Regulatory decision-making

Other pharmacovigilance activities continue between PSURs. Signal management, case processing, literature monitoring, risk management and safety communication do not stop because a PSUR has been submitted.

The PSUR provides a periodic integrated assessment of information generated by these activities.

3. What the PSUR Is Not

Several misconceptions can lead to poorly designed PSUR processes.

It is not an ICSR compilation

Individual case safety reports are an important source of evidence, but simply counting or listing cases does not constitute periodic safety evaluation.

It is not a signal-management report

Signal management is an ongoing process of detecting, validating, analysing and evaluating potential safety signals. Relevant signal information may contribute to a PSUR, but the PSUR has a broader scope.

It is not an RMP

The RMP describes the risk-management strategy and relevant pharmacovigilance and risk-minimisation activities. The PSUR evaluates what has been learned about safety during the reporting cycle and its implications for benefit-risk.

It is not merely a regulatory calendar exercise

Meeting the submission date is necessary, but submission alone does not demonstrate that the underlying safety evaluation was adequate.

4. Scope of the Safety Evaluation

The scope of the PSUR should be determined from the applicable current GVP requirements and regulatory procedure.

The assessment can draw on relevant information from multiple sources, including, as applicable:

• spontaneous and solicited individual case safety reports;
• clinical-study information;
• post-authorisation studies;
• scientific literature;
• signal-management activities;
• exposure information;
• regulatory actions and requests;
• and other relevant safety information.

The important principle is that the sources should be considered in an integrated manner where they contribute to understanding the safety profile.

5. New Information Versus Cumulative Knowledge

A PSUR has a defined reporting interval, but its scientific interpretation is not restricted to information first observed during that interval.

The report should distinguish between:

1. information that became available during the reporting period;
2. information already known from previous periods; and
3. new conclusions that arise when the information is evaluated in its cumulative context.

This distinction prevents two opposite errors.

The first is to treat every observation during the interval as though it were a newly discovered risk. The second is to overlook a developing trend because individual components were already known separately.

6. Relationship to Benefit-Risk Evaluation

Safety information acquires regulatory significance through its effect, or potential effect, on the overall benefit-risk balance.

A new adverse reaction does not automatically make a medicinal product's benefit-risk balance unfavourable. Conversely, the absence of a formally validated signal does not mean that emerging information can be ignored.

The evaluation should consider the strength and limitations of the evidence, the clinical seriousness of the issue, the affected population, exposure, the magnitude and relevance of the benefit, and the availability and effectiveness of risk-management measures where applicable.

The conclusion should explain the reasoning rather than simply state that the benefit-risk balance remains positive.

7. Who Uses the PSUR?

The immediate regulatory users include the relevant competent authorities and, within applicable EU procedures, the regulatory bodies involved in the assessment of periodic safety information.

For the MAH, the PSUR is also an important internal governance document.

It can provide evidence for decisions concerning:

• signal evaluation;
• risk-management activities;
• additional pharmacovigilance activities;
• risk-minimisation measures;
• product information;
• regulatory interactions;
• and further investigation of safety concerns.

The QPPV and relevant safety governance functions should therefore understand the PSUR as part of the broader PV system rather than as an isolated aggregate-reporting deliverable.

8. PSUR and Regulatory Oversight

The regulatory value of the PSUR lies partly in its ability to provide a structured periodic review of evidence across products and regulatory contexts.

Where the applicable EU procedure involves assessment of periodic safety information across relevant products or active substances, the PSUR contributes to a common regulatory evaluation.

This is closely associated with the PSUSA concept, but the terms should not be confused.

The PSUR is the safety report submitted for assessment. PSUSA refers to the applicable EU regulatory assessment procedure for periodic safety information.

9. PSUR and the EURD Framework

For substances subject to the European Union periodic reporting system, the European Union reference date (EURD) framework is an important component of determining the applicable reporting schedule.

The current EURD list should be consulted rather than relying on an historical internal calendar.

An effective organisational process should therefore control:

• identification of applicable substances;
• confirmation of the relevant reference date;
• reporting frequency;
• submission deadline;
• changes to the applicable schedule;
• and communication of schedule changes to responsible functions.

The regulatory calendar is therefore itself a controlled pharmacovigilance process.

10. PSUR Scope and Product Differences

The applicable PSUR requirements can depend on the regulatory and product context.

Factors requiring consideration may include:

• the active substance;
• authorised indications;
• regulatory procedure;
• number of relevant marketing authorisations;
• product formulations or presentations;
• differing exposure populations;
• and applicable regulatory requirements.

The organisation should establish the applicable scope before data collection and drafting begin.

An incorrect scope at project initiation can propagate through the entire report and create downstream reconciliation problems.

11. The Reporting Interval and Data Lock Point

The reporting interval defines the period covered by the periodic assessment.

The data lock point (DLP) establishes the controlled point at which the principal reporting data set is closed for the reporting period.

The DLP should not be treated as merely an administrative date. It is a critical control point because data completeness, analysis and subsequent review depend on knowing which information belongs to the defined reporting data set.

The treatment of information that becomes available after the DLP should follow the applicable current guidance and the organisation's controlled procedures.

12. Why the Scope Must Be Defined Before Writing

A PSUR should not begin with authors opening a previous report and replacing dates.

The team should first establish:

What product / substance?
        ↓
What regulatory scope?
        ↓
What reporting interval?
        ↓
What DLP?
        ↓
What sources are required?
        ↓
What safety questions require evaluation?

This creates a controlled foundation for the subsequent data collection and scientific assessment.

13. Inspection Perspective

An inspection can test whether the organisation can demonstrate that the PSUR's scope and purpose were understood before preparation began.

Evidence may include:

• regulatory-calendar records;
• EURD monitoring;
• project plans;
• defined responsibilities;
• data-source inventories;
• DLP confirmation;
• review records;
• escalation records;
• and documented decisions concerning scope or unusual data situations.

An organisation that can produce a final PSUR but cannot explain how it established the applicable scope has a weaker control environment than one that can demonstrate the complete decision trail.

14. Common Failure Modes

Potential weaknesses include:

• using an obsolete reporting schedule;
• failing to establish the correct regulatory scope;
• treating the PSUR as a case-counting exercise;
• failing to integrate relevant signal information;
• confusing the PSUR with the RMP;
• failing to distinguish new information from cumulative knowledge;
• inadequate control of the DLP;
• and producing conclusions that are not connected to the evidence.

These are potential process deficiencies, not assertions that every example constitutes a formal regulatory finding.

15. Practical Decision Framework

When determining whether information belongs in the PSUR evaluation, ask:

1. Is the information relevant to the medicinal product or active substance within scope?
2. Did it become available during the relevant reporting period, or is it important cumulative information?
3. Is it relevant to the safety profile or benefit-risk assessment?
4. Does it interact with an existing signal, risk, missing-information issue or regulatory concern?
5. What is the appropriate level of analysis?
6. Does it require action beyond inclusion in the PSUR?

This approach keeps the PSUR focused on regulatory safety evaluation rather than indiscriminate information accumulation.

Key Takeaways

• The PSUR is a periodic scientific and regulatory safety evaluation.
• Its purpose is broader than compilation of ICSRs or signal-management output.
• The evaluation integrates new information with relevant cumulative knowledge.
• The ultimate question is what the evidence means for the safety profile and benefit-risk balance.
• The applicable scope and reporting schedule should be established before preparation begins.
• The current EURD framework is an important source for applicable periodic-reporting schedules where relevant.
• PSUR and PSUSA are related but distinct concepts.
• A controlled DLP is an important operational milestone.
• Inspection readiness requires evidence of how scope, data, analysis and conclusions were controlled.

References

1. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module VII — Periodic Safety Update Report.
2. European Medicines Agency. Good Pharmacovigilance Practices (GVP), current GVP index and revision information.
3. European Medicines Agency. European Union reference dates (EURD) list and frequency of submission of PSURs.
4. European Medicines Agency. PSUR Repository and PSUSA procedural guidance.
5. European Commission. Commission Implementing Regulation (EU) No 520/2012, as amended.
6. European Parliament and Council. Directive 2001/83/EC, as amended.
7. Regulation (EC) No 726/2004, as amended.

Regulatory Note

This article is an educational explanation of the scope, objectives and regulatory purpose of the EU PSUR. It does not replace current GVP Module VII, applicable EU legislation, the current EURD list, EMA procedural guidance, PSUR Repository requirements, or an organisation's approved procedures.

Regulatory requirements and supporting procedures may change. Before preparing or submitting a PSUR, the current applicable regulatory documents, reporting schedule, procedure and technical requirements should be verified.

Examples and inspection considerations in this article are illustrative unless an authoritative source is specifically identified.

16. Information Relevant to the Periodic Safety Evaluation

The PSUR should evaluate relevant information that can contribute to understanding the safety profile and benefit-risk balance during the reporting interval and cumulatively.

The important word is relevant. A PSUR is not intended to become an uncontrolled repository of every piece of information received by the organisation.

The preparation process should therefore identify the information sources that can materially contribute to the assessment and establish appropriate interfaces with the processes that generate or evaluate that information.

Depending on the product and circumstances, relevant information can include:

• individual case safety reports;
• clinical-trial and other clinical-study information;
• post-authorisation studies;
• scientific literature;
• signal-management outputs;
• exposure information;
• regulatory actions and requests;
• product-use information;
• and other evidence relevant to safety or benefit-risk evaluation.

The exact composition of the evidence base should follow the applicable current Module VII requirements and the product's regulatory context.

17. Individual Case Safety Reports as Evidence

ICSRs are an important component of PSUR safety evaluation, but the PSUR should not be reduced to a count of cases.

Case information can contribute to the assessment of:

• newly observed adverse reactions;
• changes in the characteristics of known reactions;
• seriousness and clinical outcomes;
• patterns within particular populations;
• medication errors and other special situations where relevant;
• and potential signals requiring further evaluation.

The interpretation should consider the limitations of spontaneous reporting, including under-reporting, stimulated reporting, incomplete clinical information, reporting bias and changes in exposure or reporting behaviour.

An increase in the number of reports therefore does not, by itself, demonstrate an increase in incidence or risk.

18. Clinical-Study Information

Clinical studies can provide information that is complementary to spontaneous reporting.

Depending on the applicable scope, relevant information can include safety findings from clinical trials and other studies conducted during the reporting period, as well as important cumulative findings.

Study-derived information can be particularly valuable because the denominator, study population, follow-up and data-collection methods may be more controlled than in spontaneous reporting.

However, study data also have limitations. A clinical-study population may differ substantially from the population receiving the product in routine clinical practice, and the duration or size of a study may be insufficient to detect rare or delayed events.

The PSUR should therefore interpret study findings in their appropriate clinical and methodological context.

19. Post-Authorisation Studies

Post-authorisation studies may provide important evidence about risks, utilisation patterns, outcomes or effectiveness of risk-management measures.

Relevant findings should be incorporated into the periodic safety evaluation where they contribute to understanding the product's safety profile or benefit-risk balance.

The PSUR should not reproduce an entire study report merely because a study exists. It should present the findings necessary for the safety assessment and explain their regulatory significance.

Where a study identifies a new safety concern, the organisation should also consider whether action is required through another PV or regulatory pathway rather than waiting for the next periodic report.

20. Scientific Literature

Scientific literature can provide evidence about adverse reactions, safety signals, epidemiology, mechanisms, class effects, pregnancy outcomes and other matters relevant to the safety profile.

Literature information should be assessed according to the nature and reliability of the evidence rather than simply counted as another source of reports.

A published case report, a comparative observational study, a meta-analysis and a mechanistic paper do not carry the same evidentiary meaning.

The PSUR should therefore distinguish the type of evidence and consider methodological limitations when drawing conclusions.

The operational process for medical literature monitoring is a separate subject and should not be confused with the role of literature evidence in the PSUR.

21. Signal Management and the PSUR

Signal management is continuous. The PSUR provides a periodic opportunity to integrate relevant signal-management conclusions into the broader safety evaluation.

The PSUR may therefore need to consider:

• validated signals;
• signals under evaluation;
• signals closed during the reporting interval;
• emerging safety concerns;
• and regulatory actions resulting from signal evaluation.

The PSUR should not create a parallel signal-management system.

Instead, the PSUR should use controlled information from the signal-management process and explain its implications for the overall safety assessment.

22. Safety Information That Requires Action Before the PSUR

A critical principle is that the PSUR is not a substitute for immediate safety escalation.

If important new safety information arises that requires urgent assessment or regulatory action, the organisation should use the applicable immediate safety-reporting, signal-management, regulatory or safety-communication pathway.

The existence of a forthcoming PSUR does not justify waiting for the periodic reporting cycle when the circumstances require earlier action.

The PSUR can subsequently document and evaluate the information within the periodic context.

This distinction prevents the PSUR timetable from becoming an unintended delay mechanism.

23. New Information During the Reporting Interval

For each important item of new information, the assessment should consider whether it changes the understanding of an existing risk, introduces a potential new concern or provides evidence against a previously suspected concern.

A useful analytical sequence is:

New information
      ↓
Clinical and methodological assessment
      ↓
Relationship to existing knowledge
      ↓
Effect on safety profile
      ↓
Effect on benefit-risk balance
      ↓
Need for action?

The conclusion should be proportionate to the strength of the evidence.

24. Cumulative Evaluation

The cumulative perspective is essential because important safety conclusions may emerge only after information from several reporting periods is considered together.

For example, a small number of reports in each individual interval may become meaningful when examined alongside:

• increasing exposure;
• consistent clinical features;
• supporting literature;
• study evidence;
• a plausible mechanism;
• or similar observations with related products.

Conversely, a pattern that initially appears concerning may become less compelling when cumulative evidence fails to confirm the suspected association.

Periodic evaluation therefore involves interpretation of the trajectory of knowledge, not merely the newest data.

25. Exposure and Use Context

Safety information should be interpreted in relation to the population exposed to the product.

Relevant context can include, where appropriate:

• estimated patient exposure;
• treatment duration;
• indication;
• age and other population characteristics;
• geographical distribution;
• dose and formulation;
• and changes in prescribing or utilisation.

Exposure estimates are not necessarily precise measurements of the number of treated patients. Their assumptions and limitations should be understood when interpreting reporting patterns.

A doubling of reports can have a very different meaning if exposure has also doubled.

26. Efficacy and Effectiveness in the Benefit-Risk Context

The safety assessment cannot be separated completely from therapeutic benefit.

Information about efficacy or effectiveness can therefore be relevant to the benefit-risk evaluation, particularly where new evidence changes the magnitude, duration or applicability of therapeutic benefit.

This does not turn the PSUR into a general clinical-development report. The information should be considered insofar as it affects the assessment of the benefit-risk balance within the applicable regulatory framework.

27. Population-Specific Evidence

Safety findings may differ across populations.

Where relevant, the assessment should consider information relating to groups such as:

• children;
• older adults;
• pregnant or breastfeeding women;
• patients with renal or hepatic impairment;
• patients receiving particular concomitant medicines;
• and other clinically relevant subgroups.

A low overall reporting frequency can conceal a clinically important risk concentrated in a particular population.

Conversely, an apparent population-specific pattern may reflect differences in exposure, ascertainment or reporting rather than a true difference in risk.

28. Special Situations

Special situations can contribute to the periodic safety evaluation even when they do not all represent conventional adverse-reaction reports.

Examples can include:

• medication errors;
• overdose;
• misuse or abuse;
• off-label use;
• occupational exposure;
• pregnancy exposure;
• and lack of efficacy where relevant to the product and indication.

The appropriate treatment depends on the nature of the information and the applicable regulatory framework.

The PSUR should reflect safety-relevant information appropriately without confusing different PV classifications.

29. Data Quality and Limitations

The PSUR should make important limitations visible.

Examples include:

• incomplete case information;
• uncertain exposure estimates;
• small sample sizes;
• confounding;
• missing follow-up;
• under-reporting;
• reporting stimulation;
• differences in data sources;
• and methodological limitations of studies.

A limitation does not automatically invalidate the evidence. It determines how confidently the evidence can support a conclusion.

A strong safety evaluation therefore distinguishes absence of evidence from evidence of absence.

30. Avoiding Double Counting

Information can enter the pharmacovigilance system through more than one pathway.

For example, a case may appear in:

• the ICSR database;
• a literature-monitoring output;
• a clinical-study database;
• a partner database;
• and a safety-analysis dataset.

The PSUR process should use controlled data and appropriate reconciliation to avoid treating the same underlying evidence as multiple independent observations.

This is particularly important when combining quantitative analyses from different sources.

31. Cross-Functional Interfaces

The PSUR depends on information from multiple functions.

Potential contributors can include:

• Pharmacovigilance;
• Clinical Development;
• Epidemiology;
• Medical Affairs;
• Regulatory Affairs;
• Quality;
• Risk Management;
• Clinical Operations;
• and external partners.

The responsibility for the final scientific assessment should nevertheless remain clear.

A PSUR can have many contributors without having many competing owners of the final conclusion.

32. PSUR Versus Other PV Processes

The following distinction is useful:

These processes interact continuously, but none should be treated as a replacement for another.

33. Practical Scenario: More Cases but No Change in Risk

Suppose reports of an adverse reaction increase substantially during the reporting interval.

Before concluding that risk has increased, the PSUR assessment should consider:

• exposure;
• reporting behaviour;
• changes in awareness;
• regulatory or communication activity;
• changes in utilisation;
• case characteristics;
• seriousness and outcomes;
• and other supporting evidence.

An increase in reporting may reflect increased exposure or stimulated reporting rather than an increase in the underlying incidence.

The PSUR should explain the evidence supporting the conclusion.

34. Practical Scenario: A New Signal Near the DLP

Suppose a potential safety signal is identified shortly before the DLP.

The organisation should determine its status using the applicable signal-management process and assess how the information should be represented in the PSUR.

The DLP should not be used as a reason to ignore important information, nor should the PSUR become a substitute for the appropriate immediate signal-management process.

35. Practical Scenario: Study Evidence Conflicts With Spontaneous Reports

Suppose spontaneous reports suggest an association while a large observational study does not support an increased risk.

The correct response is not to select one source automatically.

The assessment should examine differences in:

• population;
• exposure;
• outcome definition;
• ascertainment;
• comparator;
• confounding;
• statistical precision;
• and biological plausibility.

The PSUR should explain how the totality of evidence affects the conclusion.

36. Practical Scenario: An Established Risk Has No New Signal

An important known risk may generate no new validated signal during a reporting interval.

That does not mean the risk has disappeared.

The PSUR should consider whether the cumulative evidence remains consistent with the existing understanding and whether current risk-management measures remain appropriate.

37. Inspection Questions

An inspector may ask:

• How did you determine which information was relevant to the PSUR?
• How were data from different PV processes integrated?
• How did you avoid double counting?
• How were signal-management findings incorporated?
• How were urgent safety issues handled before the PSUR?
• How were limitations in the evidence addressed?
• How were exposure changes considered?
• How were conflicting sources reconciled?
• How did you distinguish new information from cumulative knowledge?
• What evidence supports the final conclusions?

The organisation should be able to demonstrate a controlled process rather than reconstruct the rationale retrospectively.

38. Key Takeaways

The PSUR should evaluate relevant evidence as an integrated safety assessment rather than as an inventory of PV activity.

ICSRs, studies, literature, signals, exposure and regulatory information can each contribute different types of evidence. Their value depends on context, methodological quality and how they interact with cumulative knowledge.

The PSUR is also not a mechanism for delaying urgent safety action. Continuous pharmacovigilance processes remain active throughout the reporting cycle.

The strongest PSURs make uncertainty visible, distinguish different evidence types and explain why the totality of evidence does or does not alter the safety profile or benefit-risk balance.

39. From Safety Evaluation to Regulatory Conclusion

The purpose of the PSUR is ultimately to support a reasoned conclusion about the product's safety profile and benefit-risk balance.

The conclusion should follow from the evidence and analysis presented in the report. It should not be treated as a predetermined statement that the benefit-risk balance remains positive.

A useful conceptual sequence is:

Evidence
   ↓
Assessment
   ↓
Identification of safety implications
   ↓
Benefit-risk consideration
   ↓
Conclusion
   ↓
Action, if required

The strength of the conclusion should be proportionate to the strength and limitations of the evidence.

40. Possible Outcomes of the Assessment

A periodic safety evaluation may conclude that the available evidence:

• does not change the established safety profile;
• provides additional characterisation of a known risk;
• identifies an emerging safety concern requiring further evaluation;
• supports a change in the understanding of a risk;
• indicates that existing risk-minimisation measures should be reconsidered;
• or requires another regulatory or pharmacovigilance action.

The PSUR itself does not determine every subsequent regulatory action. Rather, it provides the scientific assessment that can inform the appropriate regulatory decision-making process.

41. When the Benefit-Risk Balance Remains Positive

A conclusion that the benefit-risk balance remains positive should still be supported by the evidence reviewed.

The conclusion should address why new information does not materially alter the balance.

For example, the assessment may find that:

• the new information is consistent with an already characterised risk;
• exposure-adjusted evidence does not indicate an unexpected increase in risk;
• new studies do not confirm a suspected association;
• the clinical benefit remains substantial in the relevant population;
• or existing risk-minimisation measures remain appropriate.

The exact reasoning will depend on the product and evidence.

A generic statement that no action is required, without an evidentiary explanation, provides little assurance that a meaningful assessment occurred.

42. When the Safety Profile Changes

A change in the safety profile does not necessarily mean that the medicinal product must be withdrawn or that the overall benefit-risk balance has become negative.

The assessment should distinguish between:

1. a new observation;
2. a newly characterised risk;
3. a change in the frequency, severity or characteristics of a known risk;
4. a change in the affected population;
5. a change in the effectiveness of risk-minimisation measures; and
6. a change substantial enough to alter the overall benefit-risk balance.

These are different regulatory questions and should not be collapsed into a single binary outcome.

43. Relationship With the Risk Management Plan

The PSUR and RMP are closely connected but serve different purposes.

The PSUR evaluates what has been learned about safety and benefit-risk during the relevant period and cumulatively. The RMP describes the product's risk-management strategy and the pharmacovigilance and risk-minimisation activities used to address important risks and uncertainties.

A PSUR conclusion may therefore lead to consideration of whether the RMP remains appropriate.

Examples include:

• a newly identified or important potential risk;
• changes to missing information;
• new evidence affecting an existing risk;
• a need for additional pharmacovigilance activity;
• or evidence that risk-minimisation measures require modification.

The PSUR should not simply reproduce the RMP. It should explain the safety evidence that may have implications for risk management.

44. Relationship With Signal Management

Signal management remains an ongoing process before, during and after PSUR preparation.

The PSUR can summarise and evaluate relevant signal-management outcomes, but the periodic report should not be used to postpone signal evaluation.

Where a potential signal emerges during preparation, the organisation should determine its status through the normal signal-management process and assess whether the matter requires action independently of the PSUR timetable.

The PSUR then provides the periodic context for the safety issue and its implications.

45. Relationship With Safety Communication

A PSUR conclusion can have implications for safety communication, but safety communication should follow the applicable process and timing requirements.

If an important safety issue requires communication before the PSUR is finalised, the organisation should not wait for publication or assessment of the PSUR before taking the appropriate action.

The periodic report can subsequently document the issue and assess the evidence cumulatively.

46. Regulatory Assessment of the PSUR

Within the EU regulatory system, submitted PSURs may undergo regulatory assessment according to the applicable procedure.

The assessment may consider whether the evidence supports changes to the safety profile, product information, risk-management measures or other regulatory actions.

The exact procedure depends on the medicinal product, active substance and applicable regulatory framework.

Organisations should therefore distinguish between:

• preparation and submission of the PSUR by the MAH;
• scientific assessment of the submitted information; and
• the resulting regulatory decision or action.

These are related but distinct stages.

47. PSUSA and the Periodic Assessment Process

For substances within the relevant EU periodic safety assessment framework, the PSUR may form part of a PSUSA procedure.

The existence of a PSUSA does not change the fundamental responsibility of the MAH to prepare an accurate and scientifically justified PSUR within the applicable requirements.

Nor should the MAH assume that regulatory assessment will identify all deficiencies in its own safety evaluation.

The PSUR should be internally complete and defensible before submission.

48. Actions Following a PSUR Assessment

Depending on the outcome, actions may include:

• no change to the existing safety measures;
• further monitoring;
• additional analysis;
• additional pharmacovigilance activity;
• modification of risk-minimisation measures;
• changes to product information;
• regulatory communication;
• or other measures within the applicable regulatory framework.

The organisation should maintain a controlled process for tracking actions arising from the assessment.

A PSUR process is therefore not complete merely when the report is submitted.

49. Governance After Submission

Post-submission governance should ensure that relevant assessment outcomes are communicated to the responsible functions and incorporated into appropriate PV processes.

Depending on the outcome, this can involve:

• the QPPV;
• safety governance committees;
• regulatory affairs;
• risk management;
• signal management;
• medical review;
• quality management;
• and relevant affiliates or partners.

The organisation should be able to demonstrate how significant conclusions and resulting actions were translated into operational controls.

50. Inspection Evidence

An inspection-ready PSUR process should allow the organisation to reconstruct the path from source information to regulatory conclusion.

Useful evidence can include:

• the approved PSUR project plan;
• source-data inventories;
• data extraction and reconciliation records;
• medical-review documentation;
• signal-management interfaces;
• exposure calculations and assumptions;
• review comments and resolutions;
• governance approvals;
• submission evidence;
• regulatory correspondence;
• and records demonstrating implementation of resulting actions.

The objective is not to generate paperwork for its own sake. Evidence should demonstrate that the safety evaluation was controlled, scientifically justified and traceable.

51. Practical Scenario: No Change to the Benefit-Risk Balance

A product has a well-characterised adverse reaction. During the reporting interval, reports increase moderately.

The PSUR assessment finds that exposure increased substantially, the clinical characteristics remain consistent with the known reaction and no new severity pattern is identified.

The conclusion may therefore be that the increase in reporting does not demonstrate a material change in the risk profile.

The important point is the reasoning. The conclusion should be supported by exposure, case characteristics and other relevant evidence rather than by the report count alone.

52. Practical Scenario: New Evidence Changes Risk Characterisation

A previously recognised risk is supported by new observational evidence suggesting that the risk is concentrated in a previously under-characterised subgroup.

The PSUR should assess the strength of the evidence and its implications for the existing safety specification and risk-management approach.

Possible consequences may include further investigation, additional monitoring or consideration of changes to risk-minimisation measures, depending on the evidence and regulatory context.

The PSUR documents the evaluation; the appropriate downstream process determines and implements the resulting action.

53. Practical Scenario: Risk-Minimisation Measure Appears Ineffective

Suppose a risk-minimisation measure was introduced to address an important risk, but new evidence suggests that the measure is not achieving its intended effect.

The PSUR should consider the evidence and explain its implications for the benefit-risk balance and risk-management strategy.

This may create an interface with RMP maintenance and effectiveness evaluation.

The PSUR should not simply state that the measure exists. The relevant question is whether the available evidence supports its continued adequacy.

54. Practical Scenario: Important Information Arrives After the DLP

Information received after the DLP requires careful handling.

The organisation should apply the current applicable regulatory requirements and its controlled procedures to determine whether the information belongs to the defined reporting dataset, requires separate action, or should be considered in another manner.

The critical principle is that the DLP is a controlled data boundary, not a justification for ignoring important safety information.

Where the information indicates an urgent safety concern, the appropriate immediate PV or regulatory pathway takes precedence over the periodic reporting timetable.

55. Practical Scenario: Conflicting Regulatory and Internal Conclusions

Suppose internal assessment concludes that the benefit-risk balance remains positive while a regulatory assessment raises additional concerns.

The organisation should treat the regulatory assessment and resulting requirements as controlled regulatory inputs.

The appropriate response is not to retrospectively rewrite the historical PSUR without a controlled reason. Instead, the organisation should evaluate the new information, implement required actions and determine whether subsequent PV documents or risk-management activities require updating.

56. Common PSUR Governance Failures

Potential weaknesses include:

• treating the PSUR as an annual or periodic administrative deliverable;
• weak ownership of the final scientific conclusion;
• inadequate integration with signal management;
• failure to connect conclusions to RMP governance;
• poor control of post-submission actions;
• inability to reconstruct the evidence supporting a conclusion;
• inconsistent treatment of exposure information;
• and failure to escalate important safety information outside the PSUR process when necessary.

These are practical failure modes to test for during quality review and inspection preparation. They should not be presented as universal regulatory findings unless supported by an authoritative inspection source.

57. QPPV Perspective

The QPPV should be able to understand what the PSUR says about the effectiveness and state of the pharmacovigilance system, even where detailed preparation is delegated to specialist teams.

Important questions include:

• Is the PSUR consistent with the known safety profile?
• Are significant signals and emerging risks appropriately reflected?
• Are important discrepancies between PV sources understood?
• Are conclusions supported by evidence?
• Are RMP implications identified?
• Are regulatory actions tracked?
• Does the report reveal weaknesses in underlying PV processes?

The QPPV's role is not simply to confirm that a report was submitted on time. Effective oversight requires confidence that the report reflects an appropriately functioning PV system.

58. What a Defensible PSUR Looks Like

A defensible PSUR has a clear chain of reasoning:

Defined regulatory scope
          ↓
Controlled data sources
          ↓
Complete and reconciled evidence
          ↓
Critical scientific evaluation
          ↓
Integrated safety assessment
          ↓
Benefit-risk conclusion
          ↓
Clearly identified actions
          ↓
Controlled follow-through

The strength of the final report depends on every part of this chain.

A polished document cannot compensate for an uncontrolled data source, unexplained analysis or unsupported conclusion.

59. Final Takeaways

The regulatory purpose of the PSUR is to provide a structured periodic evaluation of the medicinal product's safety profile and benefit-risk balance.

Its value lies in the quality of the assessment, not the volume of information collected.

The PSUR must operate alongside continuous ICSR processing, signal management, risk management, literature monitoring, study activities and safety communication. It should integrate their relevant outputs without replacing them.

Important safety information should be acted upon through the appropriate pathway when necessary rather than being deferred until the next PSUR.

The final conclusion should be evidence-based, transparent about uncertainty and connected to any required regulatory or pharmacovigilance action.

A mature PSUR process therefore demonstrates more than timely submission. It demonstrates that the MAH can move from information to scientific evaluation, from evaluation to benefit-risk judgement, and from judgement to controlled action.